The current pipeline of OncoBone Therapeutics includes five therapeutic assets for oncology indications involving bone metastases, such as Castration-Resistant Prostate Cancer (CRPC), Triple-Negative Breast Cancer (TNBC) and Multiple Myeloma (MM). In addition, several potential assets are under evaluation.
Click the to find out more about the therapeutic asset of each partner
OBP-001 is a first-in-class humanized immunomodulating antibody being developed for bone metastasizing malignancies. Currently on hold due to funding/licensing negotiations that are estimated to be completed in early 2026.
OBP-002 is a first-in-class small-molecule inhibitor being developed for bone metastasizing malignancies. The asset is currently in lead optimization phase.
OTX-001 is a first-in-class small-molecule inhibitor being developed for TNBC and other bone metastasizing malignancies. Proof-of-concept studies are to be completed, followed by regulatory safety and other IND-enabling studies, and out-licensing for clinical development.
OTX-002 is a first-in-class ADC being developed for MM. Proof-of-concept studies are to be completed, followed by regulatory safety and other IND-enabling studies, and out-licensing for clinical development.
OTX-003 is a first-in-class radiopharmaceutical being developed for CRPC and other bone metastasizing malignancies. Proof-of-concept studies are to be completed, followed by regulatory safety and other IND-enabling studies, and out-licensing for clinical development.